In summary, our retrospective study demonstrates that the Vimentin and POU4F2 combined methylation biomarker panel is a novel, cost-effective, and non-invasive method that offers significant sensitivity and specificity for distinguishing BC from other urinary diseases, showing potential clinical diagnostic value, particularly for patients with stage I and low-grade BC. The gene discussed is VIM; the disease is breast cancer.